NasdaqGS:GOSSBiotechs
Gossamer Bio (GOSS) Quarterly Loss Deepens To US$47 Million Testing Bullish Profitability Narrative
Gossamer Bio (GOSS) has just closed out FY 2025 with fourth quarter revenue of about US$13.8 million and a basic EPS loss of US$0.21, alongside a trailing twelve month EPS loss of US$0.75 on revenue of US$48.5 million. This sets a clear snapshot of where the business stands heading into 2026. Over recent quarters the company has seen revenue move from US$9.4 million in Q4 2024 through US$9.9 million, US$11.5 million and US$13.3 million to US$13.8 million in Q4 2025, while quarterly EPS losses...